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Abstract: Although the relationship between muscle strength and exercise capacity has 
been demonstrated in dermatomyositis without lung dysfunction, little is known about 
the association between exercise capacity and interstitial lung disease in 
dermatomyositis. Eleven patients with dermatomyositis with interstitial lung disease 
without the manifestation of muscle weakness and 12 patients with idiopathic 
interstitial pneumonia underwent the 6-minute walk test (6MWT). PaO2, creatine 
kinase, percentage predicted 6MWT distance (6MWD%), and SpO2 at rest were similar 
between patients. Percentage predicted vital capacity, carbon monoxide diffusing 
capacity (DLCO%), and SpO2 after 6MWT were higher, and exertion dyspnea was lower 
in patients with dermatomyositis than those in patients with idiopathic interstitial 
pneumonia. A positive correlation parameter(s) between 6MWD% was SpO2 after 
6MWT in patients with dermatomyositis, and were DLCO% and PaO2 in patients with 
idiopathic interstitial pneumonia. Lung dysfunction in dermatomyositis might be 
suggested as an inferior limitation factor to unnoticeable myositis in exercise capacity. 
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Dermatomyositis is an autoimmune disease characterized by myogenic changes and 
skin eruptions. 1 Various autoantibodies have been found in dermatomyositis and some 
of them preferably affect lung tissue, resulting in interstitial lung disease.2-4 For 
example, it is known that rapidly progressive interstitial lung disease likely 
accompanies typical skin lesions by anti-CADM-140 antibodies and requires intensive 
treatment with medication. On the other hand, interstitial lung disease is also found in 
dermatomyositis with anti-aminoacyl-tRNA synthetase antibodies or some other 
autoantibodies showing better prognosis.5 
Exercise capacity in dermatomyositis may decline due to complex factors including 
muscle weakness by myositis, lung dysfunction, and medication especially 
corticosteroids. Peak oxygen uptake in myositis patients with normal spirometry values 
was reported to be lower than that of healthy people, correlating to peak isometric 
torque of knee extensors.6 Moreover, aerobic training was shown to improve muscle 
strength, quality of life, and oxygen uptake in myositis patients.7 Thus, since the 
relationship between muscle strength and exercise capacity has been demonstrated, 
exercise training was suggested to be a beneficial treatment to patients with 
dermatomyositis exhibiting muscle weakness. However, exercise capacity in patients 
with dermatomyositis with interstitial lung disease has not been examined. Interstitial 
lung disease in systemic sclerosis was observed to affect exercise capacity as measured 
by the 6-minute walk test (6MWT).8 Therefore, interstitial lung disease in 
dermatomyositis seems likely reduce exercise capacity. 
Idiopathic interstitial pneumonia is a typical interstitial lung disease without muscle 
complications. In idiopathic pulmonary fibrosis, one of subtypes of idiopathic interstitial 
pneumonia, 6MWT distance (6MWD) was correlated with percentage predicted carbon 
monoxide diffusing capacity (DLCO%) and gender.9 Exercise training could also improve 
exercise capacity and quality of life in patients with idiopathic pulmonary fibrosis.10 
Our hypothesis is that if dermatomyositis patients with interstitial lung disease were 
not affected by the manifestation of muscle weakness, their exercise capacity would not 
differ from that of patients with idiopathic interstitial pneumonia concerning lung 
dysfunction. The present study aimed to compare limitation factors for exercise capacity 
between patients with interstitial lung disease accompanied by dermatomyositis and 
patients with idiopathic interstitial pneumonia retrospectively. 
 
Materials and Methods 
Subjects were consecutive adult patients referred to the Rehabilitation Division of our 
university hospital between 2008 and 2011. Thirty-nine patients with dermatomyositis 
were diagnosed by physical findings and their autoantibodies were examined. 
Interstitial lung disease was found in 20 patients of 39 by examinations including the 
pulmonary function test, high resolution CT, and/or open lung biopsy. Exclusion criteria 
for the present study were proximal muscle weakness in the extremities of less than 4 
in manual muscle testing, experience of muscular training due to muscle weakness, and 
neoplasm. Therefore, 11 patients of 20 were assigned to this study (Table 1). All patients 
were diagnosed with nonspecific interstitial pneumonia for interstitial lung disease. 
The anti-CADM-140 antibody was found in three patients, anti-aminoacyl-tRNA 
synthetase antibody (EJ and Jo-1) in five, anti U1-RNP antibody in one, and unknown 
with negative anti-aminoacyl-tRNA synthetase antibody in two. Twenty-one patients 
with idiopathic interstitial pneumonia visited our division and nine of them were 
excluded because of severe respiratory symptoms to ambulate, a history of paralytic 
disease of the central nervous system, and experience of exercise training for exertion 
dyspnea. The remaining 12 were diagnosed with idiopathic pulmonary fibrosis in six 
and nonspecific interstitial pneumonia in six. 
Clinical information was collected retrospectively from all patients by reviewing their 
medical records; gender, age, morphological measurements, duration after diagnosis, 
dose of corticosteroids, percentage predicted vital capacity (VC%), DLCO%, PaO2 of blood 
gas analysis, serum creatine kinase for myogenic activity, oxygen saturation (SpO2) at 
rest and after 6MWT, Borg dyspnea score (0 to 10 category-ratio scale) at the end of 
6MWT, and percentage predicted 6-minute walk distance (6MWD%) correcting 6MWD 
by gender, age, and morphological measurements.11 Evaluations of all patients were 
performed at the first visit to our facility to be referred for consultation on further 
treatments. They completed 6MWT without leg pain or leg discomfort. A maintenance 
dose of corticosteroids had been prescribed for five patients with dermatomyositis and 
two patients with idiopathic pulmonary fibrosis before these evaluations, while the 
remained patients had not received corticosteroids. The protocol of the study was 
approved by the Human Ethics Committee of our university. 
 
Statistical Analysis 
JMP 8 software was used for statistical analysis. Descriptive statistics (means, 
standard deviation) were performed on all dependent variables. The t-test served to 
compare patients with dermatomyositis to those with idiopathic interstitial pneumonia. 
The Fisher’s exact probability test was used for comparison of gender and number of 
patients with corticosteroid medication. A simple lineal correlation coefficient was 
determined to estimate the correlation between 6MWD% and collected parameters. 
Moreover, a comparison of 6MWD% on corticosteroid medication was performed for each 
disease. P < 0.05 was considered significant. 
 
Results 
The characteristics of patients with dermatomyositis and idiopathic interstitial 
pneumonia were similar for gender, age, height, weight, duration after diagnosis, and 
corticosteroid medication, as shown in Table 1. PaO2 was also similar, but VC% and 
DLCO% of lung function were significantly lower in patients with idiopathic interstitial 
pneumonia than those in patients with dermatomyositis (p = 0.048 and 0.0070, 
respectively). Creatine kinase in patients with dermatomyositis was as low as that in 
patients with idiopathic interstitial pneumonia. There were no significant differences in 
6MWD% and SpO2 at rest between patients with dermatomyositis and those with 
idiopathic interstitial pneumonia, whereas SpO2 after 6MWT was significantly higher 
and the Borg dyspnea score was significantly lower in patients with dermatomyositis 
than that in patients with idiopathic interstitial pneumonia (p = 0.0084 and 0.0030, 
respectively). 
A positive correlation between 6MWD% and SpO2 after 6MWT was observed in patients 
with dermatomyositis (R2=0.40, p=0.038) (Table2). In patients with idiopathic 
interstitial pneumonia, 6MWD% was positively correlated to DLCO% and PaO2 (R2=0.41, 
p=0.035 and R2=0.45, p=0.018, respectively). The Borg dyspnea score and creatine 
kinase were not related parameters to 6MWD% in patients with either disease. As the 
correlation between 6MWD% and SpO2 after 6MWT was not significant in patients 
with idiopathic interstitial pneumonia (R2=0.14, p=0.23), Figure 1 demonstrated the 
regression line for patients with dermatomyositis. Values of 6MWD% in patients with 
dermatomyositis were lower than those in patients with idiopathic interstitial 
pneumonia considering SpO2 after 6MWT. Therefore, 6MWD% was low in patients with 
dermatomyositis without a severe reduction in SpO2.  
Patients with dermatomyositis receiving corticosteroids showed significantly lower 
6MWD% than that of non-receivers (p=0.026) (Table 3). The same tendency was found 
in patients with idiopathic interstitial pneumonia, though the number of receivers was 
only two, which was too small to show significance. 
 
Discussion 
The present study showed that gender, age, morphological measurements, and duration 
after diagnosis in patients with dermatomyositis were sufficiently matched with those 
in patients with idiopathic interstitial pneumonia. However, VC%, DLCO%, and SpO2 
after 6MWT were significantly higher in patients with dermatomyositis than those in 
patients with idiopathic interstitial pneumonia, despite similar 6MWD%. Contradicting 
our hypothesis, the results suggested that patients with dermatomyositis with less 
affected by pulmonary function could manage to walk the same distance as patients 
with idiopathic interstitial pneumonia. 
 Additionally, the Borg dyspnea score was significantly lower in patients with 
dermatomyositis after 6MWT than that in patients with idiopathic interstitial 
pneumonia. No relationship was seen between the Borg dyspnea score and 6MWD% in 
patients with dermatomyositis, which suggested that perceived dyspnea may not be the 
limitation factor of exercise capacity in patients with dermatomyositis even with 
interstitial lung disease. The Borg dyspnea score after 6MWT has been reported to be 
3.0 in patients with pulmonary fibrosis, including non-idiopathic disease,12 and 2.77 in 
patients with systemic sclerosis with interstitial lung disease.13 In our study, the Borg 
dyspnea score of 2.7 in patients with dermatomyositis was similar to these observations 
on interstitial lung disease. 
In patients with idiopathic interstitial pneumonia, 6MWD% was correlated with DLCO% 
and PaO2. This result was supported by previous observations showing the significant 
relations between 6MWD and DLCO%, percent predicted forced vital capacity, resting 
AaPO2, St. George’s Respiratory Questionnaire,14 and the Medical Research Council 
scale15 in patients with idiopathic pulmonary fibrosis. Moreover, a decrease in SpO2 
during 6MWT was one of the prognostic factors for patients with idiopathic interstitial 
pneumonia.16 Thus, the parameters affecting 6MWD in patients with idiopathic 
interstitial pneumonia were baseline characteristics reflecting pulmonary dysfunction. 
Similarly to dermatomyositis, the relationship between pulmonary symptoms and 
6MWD in patients with systemic sclerosis has not been fully clarified. The dyspnea 
index in patients with systemic sclerosis with interstitial lung disease was one of the 
significant associated variables to 6MWD.8 Stronger correlations between measures of 
lung disease and 6MWD were also observed in patients with systemic sclerosis by 
removing those with lower extremity pain.9 However, patients with systemic sclerosis 
have varying degrees of musculoskeletal and peripheral vascular involvement which 
reduce exercise capacity without pulmonary impairment.17 These results make it 
difficult to define the limitations to 6MWD in patients with systemic sclerosis due to 
various complications. 
As one of the limitation parameters to 6MWD%, the value of SpO2 after 6MWT was 
positively correlated with 6MWD% in patients with dermatomyositis; however, SpO2 
was not lower than that in patients with idiopathic interstitial pneumonia. Minimum 
SpO2 during 6MWT in patients with systemic sclerosis with interstitial lung disease 
was also shown to be significantly higher than that in patients with idiopathic 
pulmonary fibrosis.9 One of the explanations for these results may be that myositis 
prevented patients from walking under muscular hypoxic conditions, such that 
6MWD% depended upon SpO2 more precisely that that in patients with idiopathic 
interstitial pneumonia. Future studies regarding muscle histology, muscle oxidative 
enzyme capacity, and other relevant factors to prove the relationship in myositis are 
necessary.18 
Another limitation parameter to 6MWD% was corticosteroid medication in patients 
with dermatomyositis. No significant difference in creatine kinase between patients 
with either disease implied well controlled myopathy by medication. The Fisher’s exact 
probability test showed no difference for the comparison of the number of patients with 
corticosteroid medication, while the dose was different. Two patients with idiopathic 
interstitial pneumonia were prescribed 4 mg and 5 mg of prednisolone a day, although 4 
mg daily to one, 6 mg daily to one, and 20 mg daily to three patients were necessary for 
months to suppress the clinical symptoms of dermatomyositis. 
Generally, chronic steroid myopathy is exceedingly rare with equivalent daily doses of < 
7.5 mg prednisolone.19 Normal serum aldolase and creatine kinase with increased 
creatinuria are considered suggestive of steroid myopathy; however, we did not examine 
creatinuria. Therefore, we could not distinguish the status of reduced 6MWD% in 
patients with dermatomyositis from steroid myopathy. In the present study, two 
patients with idiopathic interstitial pneumonia also showed low values of 6MWD% 
despite low doses of corticosteroids. In patients with pulmonary sarcoidosis, 6MWD did 
not differ regarding corticosteroids treatment, but the dose was not discussed.20 As 
there was no statistical clear evidence on dose for steroid myopathy because of the 
muscle condition of the underlying disease,19 it was difficult to refer reduced 6MWD% to 
steroid myopathy but some possibility for the relationship remained. 
Our present study is limited by the small number of patients, even though distinct 
significances were found between patients with dermatomyositis and with idiopathic 
interstitial pneumonia regarding pulmonary factors (p<0.01) as shown in Table 1. There 
is a need for larger studies to further ensure the parameters affecting exercise capacity 
in patients with dermatomyositis by tests such as multivariate regression analysis. 
Many patients with dermatomyositis were excluded from our study due to neoplasm 
with the p155/140 antibody4 because neoplasm added further complications to patients. 
The variety of antibodies in dermatomyositis made it difficult for this kind of study to 
establish the parameters affecting symptoms. Meta-analysis is required for this 
purpose. 
In conclusion, our study demonstrated exercise intolerance in patients with 
dermatomyositis with interstitial lung disease without the manifestation of muscle 
weakness. Correlated parameters to 6MWD%, i.e., SpO2 after 6MWT and 
corticosteroids medication, in patients with dermatomyositis were different from those 
with idiopathic interstitial pneumonia. As the parameters for lung function could not be 
proved to affect 6MWD% in patients with dermatomyositis, myopathy may be a possible 
factor of exercise capacity even if it is asymptomatic. However, further investigations 
are needed to confirm this correlation. 
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Tables 
Table 1. Patient characteristics. 
 Dermatomyositis 
(n = 11) 
Idiopathic 
interstitial 
pneumonia (n = 12) 
p 
Gender (f/m) 7/4 4/8 0.22 
Age (ys) 58.3 ± 10.1 64.6 ± 12.6 0.20 
Height (cm) 159 ± 6 163 ± 7 0.15 
Weight (kg) 58 ± 13 61 ± 12 0.64 
Duration after diagnosis (ys) 2.2 ± 2.7 1.7 ± 1.8 0.60 
Vital capacity (% predicted) 89 ± 20 74 ± 14 0.048* 
DLCO (% predicted) 58 ± 15 41 ± 12 0.0070* 
PaO2 (mmHg) 83 ± 8 78 ± 11 0.25 
SpO2 at rest (%) 96 ± 3 97 ± 2 0.75 
SpO2 after 6MWT (%) 94 ± 4 88 ± 6 0.0084* 
Borg score after 6MWT 2.7 ± 1.6 5.2 ± 1.6 0.0030* 
6MWD (% predicted) 80 ± 19 89 ± 16 0.25 
Creatine kinase (U/l) 169 ± 207 104 ± 55 0.33 
Corticosteroids (yes/no) 5/6 2/10 0.19 
Values are mean ± standard deviation. *p < 0.05. Abbreviations: carbon monoxide 
diffusing capacity, DLCO; 6MWT, 6-minute walk test; 6MWD, 6-minute walk distance. 
Table 2. Correlation between 6MWD% and collected parameters. 
 Dermatomyositis 
(n = 11) 
Idiopathic 
interstitial 
pneumonia (n = 12) 
 R2 p R2 p 
Duration after diagnosis (ys) 0.34 0.061 0.010 0.75 
Vital capacity (% predicted) 0.28 0.096 0.055 0.46 
DLCO (% predicted) 0.20 0.16 0.41 0.035* 
PaO2 (mmHg) 0.24 0.15 0.45 0.018* 
SpO2 at rest (%) 0.32 0.070 0.12 0.26 
SpO2 after 6MWT (%) 0.40 0.038* 0.14 0.23 
Borg score after 6MWT 0.0002 0.97 0.08 0.43 
Creatine kinase (U/l) 0.077 0.41 0.17 0.18 
*p < 0.05. Abbreviations: carbon monoxide diffusing capacity, DLCO; 6MWT, 6-minute 
walk test; 6MWD, 6-minute walk distance. 
Table 3. Comparison of 6MWD% on corticosteroids medication  
 Dermatomyositis Idiopathic interstitial 
pneumonia 
Corticosteroids   
Yes   66 ± 15 (n = 5) 65 ± 17 (n = 2) 
No   91 ± 15 (n = 6) 93 ± 12 (n = 10) 
p 0.026* 0.23 
*p < 0.05. Abbreviations: 6MWD, 6-minute walk distance. 
Figure legends 
Figure 1 
Correlation between 6MWD% and SpO2 after the 6-minute walk test. Closed circles 
represent patients with dermatomyositis (n = 11) and open circles represent those with 
idiopathic interstitial pneumonia (n = 12). The regression line is for patients with 
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